These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28516282)

  • 1. Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.
    Guan X; Xu X; Zhang M
    Neurosci Bull; 2017 Oct; 33(5):561-567. PubMed ID: 28516282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low plasma serotonin linked to higher nigral iron in Parkinson's disease.
    Jellen LC; Lewis MM; Du G; Wang X; Galvis MLE; Krzyzanowski S; Capan CD; Snyder AM; Connor JR; Kong L; Mailman RB; Brundin P; Brundin L; Huang X
    Sci Rep; 2021 Dec; 11(1):24384. PubMed ID: 34934078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease.
    Naduthota RM; Honnedevasthana AA; Lenka A; Saini J; Geethanath S; Bharath RD; Christopher R; Yadav R; Gupta AK; Pal PK
    J Neurol Sci; 2017 Nov; 382():61-65. PubMed ID: 29111022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson'sdisease: A 3T and 7T MRI study.
    Alushaj E; Handfield-Jones N; Kuurstra A; Morava A; Menon RS; Owen AM; Sharma M; Khan AR; MacDonald PA
    Neuroimage Clin; 2024; 41():103577. PubMed ID: 38377722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.
    Acosta-Cabronero J; Cardenas-Blanco A; Betts MJ; Butryn M; Valdes-Herrera JP; Galazky I; Nestor PJ
    Brain; 2017 Jan; 140(1):118-131. PubMed ID: 27836833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility.
    Martin-Bastida A; Lao-Kaim NP; Loane C; Politis M; Roussakis AA; Valle-Guzman N; Kefalopoulou Z; Paul-Visse G; Widner H; Xing Y; Schwarz ST; Auer DP; Foltynie T; Barker RA; Piccini P
    Eur J Neurol; 2017 Feb; 24(2):357-365. PubMed ID: 27982501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease.
    He N; Langley J; Huddleston DE; Chen S; Huang P; Ling H; Yan F; Hu X
    Neuroimage Clin; 2020; 28():102391. PubMed ID: 32889398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging.
    Wieler M; Gee M; Camicioli R; Martin WR
    J Neurol Sci; 2016 Feb; 361():87-91. PubMed ID: 26810522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
    Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease.
    Ariz M; Martínez M; Alvarez I; Fernández-Seara MA; Castellanos G; ; Pastor P; Pastor MA; Ortiz de Solórzano C
    J Magn Reson Imaging; 2024 Aug; 60(2):534-547. PubMed ID: 37915245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging assessment of substantia nigral iron deposition in Parkinson's disease: a meta-analysis.
    Liu GL; Zhang HW; Zha CB; Fan TW; Chen ST; Shen TT; He K
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):899-906. PubMed ID: 38375696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts.
    Langley J; He N; Huddleston DE; Chen S; Yan F; Crosson B; Factor S; Hu X
    Mov Disord; 2019 Mar; 34(3):416-419. PubMed ID: 30597635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of regional iron on the motor impairments of Parkinson's disease: A quantitative susceptibility mapping study.
    Guan X; Xuan M; Gu Q; Xu X; Huang P; Wang N; Shen Z; Xu J; Luo W; Zhang M
    J Magn Reson Imaging; 2017 May; 45(5):1335-1342. PubMed ID: 27545971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of QSM over R2* in assessment of parkinson's disease - A systematic review.
    Saikiran P;
    Neurol India; 2020; 68(2):278-281. PubMed ID: 32415005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.